Canada, Puerto Rico, Italy, Rwanda and more – the new issue of Making Access Happen goes around the globe to show how lives are changing for the better through pioneering new treatments, programs, medicines and technology.
Nick Warwick, Chief Medical Officer at Sandoz, explains what value added medicines (VAMs) are, how they are developed, and which benefits they bring not only to patients.
Value added medicines (VAMs) are an increasingly significant way to provide broader access to innovative treatment options. VAMs are generic medicines that have been enhanced in a variety of ways to better address patients’ needs – and improve patients’ lives.
Dr. Claude Cyr is a critical medical cannabis presciber. In his opinion, medical cannabis should only be used when common therapies are not effective. But what supports his thesis?
Though not without its critics, medical cannabis has been used as a therapy of last resort. Despite growing evidence that medical cannabis can offer further medical benefits, accessing this treatment can be a challenging process for patients – and can raise questions regarding dosing and treatment planning for medical professionals. Researchers and companies, including Sandoz Canada, are working to improve access to this medicine and related information.
